文献速递生殖医学

儿童癌症与血液系统疾病对诊断时精原细胞数量的负面影响:男性生育力保存队列的回顾性研究

Childhood cancer and hematological disorders negatively affect spermatogonial quantity at diagnosis: a retrospective study of a male fertility preservation cohort.
PubMed 文献 · Hum Reprod · 2023-01-01

该多中心回顾性队列研究纳入2002至2018年间101例14岁以下因生育力保存就诊的男性患儿,比较肿瘤或血液病与健康对照的精原细胞数量。结果显示患儿精原细胞减少的患病率为48.5%,高于对照的31.0%,以中枢神经系统肿瘤(56.7%)和血液病(55.6%)组最高,且7岁以下患儿减少最明显。

要点

  • 儿童肿瘤或血液病患儿治疗前精原细胞数量已显著低于健康对照(48.5% vs 31.0%)。
  • 中枢神经系统肿瘤(56.7%)和血液病(55.6%)患儿精原细胞减少患病率最高。
  • 无论何种疾病,7岁以下患儿精原细胞数量减少最明显。

核心结论

  • 儿童癌症(尤其中枢神经系统肿瘤)和严重血液系统疾病可在治疗前即影响青春期前男孩的精原细胞数量。
  • 这些患儿治疗后精原细胞耗竭及持续性不育的风险可能更高。
  • 治疗前的患者咨询和生育力保存时机不应仅基于治疗方案,还应考虑诊断和年龄。

研究设计与样本

  • 多中心回顾性队列研究,纳入2002至2018年间101例14岁以下因生育力保存就诊的男性患儿,分为实体瘤、中枢神经系统肿瘤、白血病/淋巴瘤及非恶性血液病组。
  • 分析治疗前活检组织的精原细胞数量、曲细精管生育力指数及最晚期生精细胞类型,并行睾丸体积测量。
  • 对照为基于文献中健康青春期前男孩睾丸特征汇总统计量的数据模拟。

主要发现

  • 患儿精原细胞数量减少的患病率为48.5%,健康对照为31.0%。
  • 精原细胞数量减少患病率在中枢神经系统肿瘤组为56.7%,血液病组为55.6%。
  • 血液病组中,羟基脲预治疗的镰状细胞病患儿患病率为58.3%,未暴露于羟基脲者为50%。
  • 疾病还 adversely 影响精原细胞分布和分化。
  • 无论何种疾病,7岁以下患儿精原细胞数量减少最明显。

临床怎么用

  • 作者认为,治疗前的患者咨询和生育力保存时机应不仅基于治疗方案,还应考虑诊断和年龄。

局限性

  • 出于伦理原因,无法收集健康青春期前男孩的精原细胞数量数据作为对照,故采用文献数据的统计模拟。
  • 结果解读时应考虑各(亚)组患者数量较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the impact of cancer or hematological disorders on germ cells in pediatric male patients? SUMMARY ANSWER: Spermatogonial quantity is reduced in testes of prepubertal boys diagnosed with cancer or severe hematological disorder compared to healthy controls and this reduction is disease and age dependent: patients with central nervous system cancer (CNS tumors) and hematological disorders, as well as boys <7 years are the most affected. WHAT IS KNOWN ALREADY: Fertility preservation in pediatric male patients is considered based on the gonadotoxicity of selected treatments. Although treatment effects on germ cells have been extensively investigated, limited data are available on the effect of the disease on the prepubertal male gonad. Of the few studies investigating the effects of cancer or hematologic disorders on testicular function and germ cell quantity in prepuberty, the results are inconsistent. However, recent studies suggested impairments before the initiation of known gonadotoxic therapy. Understanding which diseases and at what age affect the germ cell pool in pediatric patients before treatment is critical to optimize strategies and counseling for fertility preservation. STUDY DESIGN, SIZE, DURATION: This multicenter retrospective cohort study included 101 boys aged <14 years with extra-cerebral cancer (solid tumors), CNS tumors, leukemia/lymphoma (blood cancer), or non-malignant hematological disorders, who were admitted for a fertility preservation programme between 2002 and 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: In addition to clinical data, we analyzed measurements of testicular volume and performed histological staining on testicular biopsies obtained before treatment, at cryopreservation, to evaluate number of spermatogonia per tubular cross-section, tubular fertility index, and the most advanced germ cell type prior to chemo-/radiotherapy. The controls were data simulations with summary statistics from original studies reporting healthy prepubertal boys' testes characteristics. MAIN RESULTS AND THE ROLE OF CHANCE: Prepubertal patients with childhood cancer or hematological disorders were more likely to have significantly reduced spermatogonial quantity compared to healthy controls (48.5% versus 31.0% prevalence, respectively). The prevalence of patients with reduced spermatogonial quantity was highest in the CNS tumor (56.7%) and the hematological disorder (55.6%) groups, including patients with hydroxyurea pre-treated sickle cell disease (58.3%) and patients not exposed to hydroxyurea (50%). Disease also adversely impacted spermatogonial distribution and differentiation. Irrespective of disease, we observed the highest spermatogonial quantity reduction in patients <7 years of age. LIMITATIONS, REASONS FOR CAUTION: For ethical reasons, we could not collect spermatogonial quantity data in healthy prepubertal boys as controls and thus deployed statistical simulation on data from literature. Also, our results should be interpreted considering low patient numbers per (sub)group. WIDER IMPLICATIONS OF THE FINDINGS: Cancers, especially CNS tumors, and severe hematological disorders can affect spermatogonial quantity in prepubertal boys before treatment. Consequently, these patients may have a higher risk of depleted spermatogonia following therapies, resulting in persistent infertility. Therefore, patient counseling prior to disease treatment and timing of fertility preservation should not only be based on treatment regimes, but also on diagnoses and age. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by Marie Curie Initial Training Network (ITN) (EU-FP7-PEOPLE-2013-ITN) funded by European Commision grant no. 603568; ZonMW Translational Adult stem cell research (TAS) grant no. 116003002. No competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Masliukaite I, Ntemou E, Feijen EAM, et al. Childhood cancer and hematological disorders negatively affect spermatogonial quantity at diagnosis: a retrospective study of a male fertility preservation cohort. Hum Reprod. 2023. PMID: 36708005. doi:10.1093/humrep/dead004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。